Publications by authors named "Samuel Workenhe"

Claim this Profile
O
Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models.
Jacob G E Yates, Lily Chan, Alyssa E Bogle, Elena S B Campbell, Arielle N Gillies, Samuel T Workenhe

Mol Ther Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Level of Expression of MHCI-Presented Neoepitopes Influences Tumor Rejection by Neoantigen-Specific CD8+ T Cells.
Li Deng, Scott R Walsh, Andrew Nguyen, Jordon M Inkol, Michael J Westerveld, Samuel T Workenhe

Cancer Immunol Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.
Jordon M Inkol, Michael J Westerveld, Shayla G Verburg, Scott R Walsh, Jodi Morrison, Samuel T Workenhe

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants for Antitumor and Protumor Effects of Programmed Cell Death.
Samuel T Workenhe, Jordon M Inkol, Michael J Westerveld, Shayla G Verburg, Sarah M Worfolk

Cancer Immunol Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.
Huy-Dung Hoang, Aida Said, Nasana Vaidya, Victoria H Gilchrist, Kyle Malone, Samuel T Workenhe

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LAMP3/CD63 Expression in Early and Late Endosomes in Human Vaginal Epithelial Cells Is Associated with Enhancement of HSV-2 Infection.
Aisha Nazli, Ryan Chow, Muhammad Atif Zahoor, Samuel Tekeste Workenhe, Tushar Dhawan

J Virol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral-mediated activation and inhibition of programmed cell death.
Shayla Grace Verburg, Rebecca Margaret Lelievre, Michael James Westerveld, Jordon Marcus Inkol, Yi Lin Sun, Samuel Tekeste Workenhe

PLoS Pathog· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner.
Nader El-Sayes, Alyssa Vito, Omar Salem, Samuel Tekeste Workenhe, Yonghong Wan

Int J Mol Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells.
Alyssa Vito, Omar Salem, Nader El-Sayes, Ian P MacFawn, Ana L Portillo, Samuel T Workenhe

Commun Biol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic modification of oncolytic viruses to enhance antitumor immunity.
Maria Eugenia Davola, Alyssa Vito, Jiarun Wei, Nader El-Sayes, Samuel Workenhe

Methods Enzymol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-intrinsic determinants of immunogenic cell death modalities.
Samuel T Workenhe, Jonathan Pol, Guido Kroemer

Oncoimmunology· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRIM26 Facilitates HSV-2 Infection by Downregulating Antiviral Responses through the IRF3 Pathway.
Tushar Dhawan, Muhammad Atif Zahoor, Nishant Heryani, Samuel Tekeste Workenhe, Aisha Nazli

Viruses· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines in oncolytic virotherapy.
Jonathan G Pol, Samuel T Workenhe, Prathyusha Konda, Shashi Gujar, Guido Kroemer

Cytokine Growth Factor Rev· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.
Samuel T Workenhe, Andrew Nguyen, David Bakhshinyan, Jiarun Wei, David N Hare

Commun Biol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.
Jonathan G Pol, Matthew J Atherton, Kyle B Stephenson, Byram W Bridle, Samuel T Workenhe

J Immunother Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.
Nikolas Tim Martin, Dominic Guy Roy, Samuel Tekeste Workenhe, Diana J M van den Wollenberg, Rob C Hoeben

Sci Rep· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.
Chadi Zakaria, Polen Sean, Huy-Dung Hoang, Louis-Phillipe Leroux, Margaret Watson, Samuel Tekeste Workenhe

PLoS Pathog· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Jonathan G Pol, Sarah Lévesque, Samuel T Workenhe, Shashi Gujar, Fabrice Le Boeuf

Oncoimmunology· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.
Andrew Nguyen, Louisa Ho, Samuel T Workenhe, Lan Chen, Jonathan Samson

Cell Rep· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
Jacob P van Vloten, Samuel T Workenhe, Sarah K Wootton, Karen L Mossman, Byram W Bridle

J Immunol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Samuel T Workenhe, Meghan L Verschoor, Karen L Mossman

Future Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus guidelines for the detection of immunogenic cell death.
Oliver Kepp, Laura Senovilla, Ilio Vitale, Erika Vacchelli, Sandy Adjemian, Samuel T Workenhe

Oncoimmunology· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
Samuel T Workenhe, Graydon Simmons, Jonathan G Pol, Brian D Lichty, William P Halford

Mol Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.
Samuel T Workenhe, Karen L Mossman

Oncoimmunology· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Samuel T Workenhe, Jonathan G Pol, Brian D Lichty, Derek T Cummings, Karen L Mossman

Cancer Immunol Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis